Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $14.20

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.90.

GOVX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a report on Wednesday. D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research note on Thursday, April 10th. Finally, Alliance Global Partners lowered their price objective on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research note on Tuesday.

GeoVax Labs Stock Performance

GOVX stock opened at $0.90 on Thursday. The company has a 50 day moving average price of $1.39 and a two-hundred day moving average price of $1.96. The stock has a market capitalization of $12.49 million, a P/E ratio of -0.16 and a beta of 3.70. GeoVax Labs has a one year low of $0.73 and a one year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. Research analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at $97,000. Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs in the fourth quarter worth about $104,000. Northern Trust Corp acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at about $29,000. Finally, Geode Capital Management LLC raised its holdings in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the period. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.